NASHVILLE, Tennessee ― Targeting relevant sleep problems for patients with refractory temporal lobe epilepsy (TLE) improves cognition, results of a new, double-blind, randomized controlled trial ...
~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies & ...
LEXINGTON, Mass. and AMSTERDAM, Sept. 05, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs ...
LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
Scientists say they have identified a critical new step in how brain cells function in people with one of the most common forms of epilepsy. This could lead to new treatment approaches for people with ...
(RTTNews) - Elekta AB Ser. B (EKTA-B.ST) announced that the U.S. Food and Drug Administration has granted 510(k) clearance for its Leksell Gamma Knife radiosurgery system to treat refractory, ...
- First subject received unilateral administration of NRTX-1001 in a new non-MTS cohort; no significant surgical complications or adverse events reported to date - - Data from this non-MTS cohort, ...
Please provide your email address to receive an email when new articles are posted on . Surgery for mesial temporal lobe epilepsy correlated with a reduction in imaging-defined brain age, indicating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results